Novavax (NVAX) Tops Q4 EPS by 2c

Novavax (NASDAQ: NVAX) reported Q4 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $5.45 million.

As of December 30, 2016, the company had $235.5 million in cash and cash equivalents and marketable securities compared to $230.7 million as of December 31, 2015. Net cash used in operating activities for the full year 2016 was $255.5 million, compared to $126.1 million for same period in 2015. The increase in cash usage was primarily due to increased costs relating to our RSV F Vaccine and higher employee-related costs.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook